Revenue
2022
2023
2024
2025
Envoy Medical, Inc. (COCH)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $241,000 | $225,000 | $316,000 | $237,000 | — |
| Research & development | $12.5M | $10.2M | $9.0M | $5.0M | — |
| Operating expenses | — | — | — | $4.9M | $5.2M |
| Operating income | −$22.3M | −$19.3M | −$18.4M | −$8.7M | −$5.2M |
| Net income | −$23.8M | −$20.8M | −$29.9M | −$15.9M | −$251,633 |
| Basic EPSper diluted share | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
| Diluted EPSper diluted share | -$1.23 | -$1.49 | -$2.54 | -$1.57 | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026Form 4 | TAYLOR GLEN ATenPercentOwner | BuyClass A Common Stock | 18.75M | $0.40 | $7.50M | 21.70M |
| Feb 12, 2026Form 4 | TAYLOR GLEN ATenPercentOwner | BuyWarrant Shares (Series A-2) · derivative | 18.75M | $0.00 | $0.00 | 18.75M |
| Feb 12, 2026Form 4 | TAYLOR GLEN ATenPercentOwner | BuyWarrant Shares (Series A-1) · derivative | 11.25M | $0.00 | $0.00 | 11.25M |
| Feb 12, 2026Form 4 | Patel Mona ChetanDirector | BuyClass A Common Stock | 312.5K | $0.40 | $125.0K | 332.5K |
| Feb 12, 2026Form 4 | Patel Mona ChetanDirector | BuyWarrant (right to buy) · derivative | 312.5K | $0.00 | $0.00 | 312.5K |